Apr. 24 at 1:59 PM
$LABT
Lakewood-Amedex Biotherapeutics Chairman Doug Manion said the listing will enable the company to accelerate the development of its bisphosphocin class of compounds.
This includes the company’s lead product, Nu-3, which is being developed as a potential treatment for infected diabetic foot ulcers.